OptimizeRx Cuts 2026 Revenue Guidance

The company lowered its fiscal 2026 revenue outlook after reporting third-quarter revenue that fell 17% year over year.

Updated on Nov. 12, 2026 in Economic Indicators

OptimizeRx lowered its fiscal 2026 revenue guidance to $87 million to $93 million from $95 million to $100 million, and its shares fell 20.11% to $7.15 in after-hours trading. Third-quarter revenue came in at $21.62 million, beating analyst estimates.

Why it matters

The revision reflects lower in-year contracted revenue, a signal that closely tracks the company's near-term financial trajectory for investors. The company also pointed to growth in contracted revenue for 2027 and renewed fourth-quarter spending from a previously significant customer.

Third-quarter revenue of $21.62 million declined 17% year over year but beat the $21.23 million analyst estimate, while the revised fiscal 2026 revenue range of $87 million to $93 million sits below the prior $95 million to $100 million outlook. Management did not indicate how much of the shortfall in in-year contracted revenue will be recouped.

The players

OptimizeRx

OptimizeRx is a publicly traded U.S. digital health company that provides pharmaceutical marketing and patient-engagement technology.

The details

OptimizeRx reported third-quarter non-GAAP earnings of $0.20 per diluted share, above the $0.14 estimate, and GAAP net income of $1.2 million, or $0.06 per diluted share. Adjusted EBITDA rose 23% to $6.3 million, and the company maintained its fiscal 2026 adjusted EBITDA outlook of $21 million to $25 million.

Wednesday: OptimizeRx reported third-quarter results and cut its fiscal 2026 revenue guidance, sending shares down 20.11% after hours.
Wednesday: Shares closed at $8.95 in regular trading, down 4.28% before the after-hours decline.

Macro View

The revised $87 million to $93 million range steps down from the company's earlier $95 million to $100 million fiscal 2026 outlook, a revision that shows how contracted-revenue timing can reset a company's full-year projections even when quarterly results beat estimates.

For investors holding OptimizeRx shares, the guidance cut and after-hours drop to $7.15 reset the value of positions that have already fallen 44.58% over the past 12 months. Readers weighing the stock should watch whether the company's cited 2027 contracted-revenue growth shows up in future filings.

The takeaway

Strong quarterly earnings can still coincide with a lower full-year outlook, so investors should read revised guidance alongside the reasons management gives for it. Watching how contracted revenue and customer spending develop in coming quarters will show whether the revision was a timing issue or a longer-term shift.